Bio-Path Holdings, Inc. (BPTH)
OTCMKTS
· Delayed Price · Currency is USD
0.1410
+0.0010 (0.71%)
Apr 25, 2025, 2:05 PM EDT
Bio-Path Holdings Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
1.20M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 43.26M |
Bio-Path Holdings News
- 4 weeks ago - Bio-Path GAAP EPS of -$4.12 - Seeking Alpha
- 4 weeks ago - Bio-Path Holdings Reports Full Year 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 2 months ago - ARMISTICE CAPITAL, LLC Acquires Significant Stake in Bio-Path Holdings Inc - GuruFocus
- 2 months ago - Bio-Path Holdings Provides Key Clinical Updates - GlobeNewsWire
- 2 months ago - Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia - GlobeNewsWire
- 3 months ago - Bio-Path Holdings Provides 2025 Clinical and Operational Update - GlobeNewsWire
- 4 months ago - Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity - GlobeNewsWire